PharmaCyte Biotech, Inc. financial data

Symbol
PMCB on Nasdaq
Location
Las Vegas, NV
Fiscal year end
30 April
Latest financial report
17 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1178% % 102%
Debt-to-equity 24% % -27%
Return On Equity -7.8% % -115%
Return On Assets -6.2% % -117%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 10,735,649 shares 56%
Common Stock, Shares, Outstanding 10,735,649 shares 55%
Entity Public Float $12,527,115 USD -31%
Common Stock, Value, Issued $2,602 USD 20%
Weighted Average Number of Shares Outstanding, Basic 9,262,829 shares 33%
Weighted Average Number of Shares Outstanding, Diluted 9,262,829 shares 33%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $0 USD
Research and Development Expense $456,089 USD 12%
General and Administrative Expense $4,929,032 USD -32%
Operating Income (Loss) $5,385,121 USD 17%
Nonoperating Income (Expense) $2,103,493 USD -92%
Net Income (Loss) Attributable to Parent $3,281,628 USD -116%
Earnings Per Share, Basic -0.52 USD/shares -172%
Earnings Per Share, Diluted -0.52 USD/shares -172%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $20,165,535 USD 23%
Marketable Securities, Current $372,251 USD -0.1%
Assets, Current $20,696,450 USD 22%
Intangible Assets, Net (Excluding Goodwill) $1,549,427 USD 0%
Assets $55,873,565 USD 27%
Accounts Payable, Current $1,200,082 USD 147%
Accrued Liabilities, Current $445,656 USD -37%
Liabilities, Current $1,678,229 USD 41%
Liabilities $16,471,229 USD 360%
Accumulated Other Comprehensive Income (Loss), Net of Tax $21,540 USD 12%
Retained Earnings (Accumulated Deficit) $100,000,171 USD -3.4%
Stockholders' Equity Attributable to Parent $38,113,013 USD -5.3%
Liabilities and Equity $55,873,565 USD 27%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $1,993,981 USD -434%
Net Cash Provided by (Used in) Financing Activities $0 USD
Net Cash Provided by (Used in) Investing Activities $0 USD
Common Stock, Shares Authorized 200,000,000 shares 0%
Common Stock, Shares, Issued 26,005,715 shares 20%
Common Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $1,993,858 USD 89%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $20,165,535 USD 23%
Deferred Tax Assets, Valuation Allowance $15,221,718 USD 0.18%
Deferred Tax Assets, Gross $16,914,188 USD 4.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $3,278,682 USD -116%
Deferred Tax Assets, Operating Loss Carryforwards $15,026,112 USD 4.1%
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Additional Paid in Capital $183,141,663 USD 0.95%
Deferred Tax Assets, Net of Valuation Allowance $15,221,718 USD 0.18%